Jonathan Wolleben
Stock Analyst at Citizens JMP
(4.89)
# 296
Out of 5,023 analysts
701
Total ratings
52.2%
Success rate
22.5%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Reiterated: Buy | $12 → $27 | $9.14 | +195.40% | 22 | Oct 1, 2026 | |
| QNCX Quince Therapeutics | Upgraded: Buy | $77 | $29.20 | +163.70% | 6 | Sep 22, 2026 | |
| PHVS Pharvaris | Reiterated: Buy | $74 → $79 | $31.19 | +153.29% | 35 | Sep 9, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $165 → $170 | $140.06 | +21.38% | 38 | Aug 31, 2026 | |
| SION Sionna Therapeutics | Downgraded: Hold | n/a | $4.91 | - | 2 | Aug 10, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $113 → $110 | $27.67 | +297.54% | 26 | Aug 7, 2026 | |
| BMEA Biomea Fusion | Reiterated: Buy | $9 → $7 | $1.27 | +451.18% | 2 | Aug 6, 2026 | |
| MIRM Mirum Pharmaceuticals | Reiterated: Buy | $146 → $137 | $82.93 | +65.20% | 33 | Aug 6, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $152 → $160 | $92.83 | +72.36% | 22 | Aug 5, 2026 | |
| ANNX Annexon | Initiated Coverage: Sell | $3 | $4.19 | -28.40% | 1 | Jul 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $745 → $739 | $499.40 | +47.98% | 62 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 | $10.55 | +421.33% | 45 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $11 | $2.74 | +302.19% | 81 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $170 → $150 | $45.71 | +228.16% | 28 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $11 | $4.58 | +140.17% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $25 | $2.70 | +825.93% | 3 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 → $86 | $58.51 | +46.98% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $28 | $8.17 | +242.72% | 49 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.64 | +389.30% | 42 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.96 | - | 63 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $11 | $4.81 | +128.69% | 17 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $2.96 | +508.11% | 41 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 → $32 | $1.68 | +1,804.76% | 7 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $6.09 | n/a | 27 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $17.11 | n/a | 42 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $26.82 | n/a | 1 | May 12, 2023 |
Sagimet Biosciences
Oct 1, 2026
Reiterated: Buy
Price Target: $12 → $27
Current: $9.14
Upside: +195.40%
Quince Therapeutics
Sep 22, 2026
Upgraded: Buy
Price Target: $77
Current: $29.20
Upside: +163.70%
Pharvaris
Sep 9, 2026
Reiterated: Buy
Price Target: $74 → $79
Current: $31.19
Upside: +153.29%
Protagonist Therapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $165 → $170
Current: $140.06
Upside: +21.38%
Sionna Therapeutics
Aug 10, 2026
Downgraded: Hold
Price Target: n/a
Current: $4.91
Upside: -
Structure Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $113 → $110
Current: $27.67
Upside: +297.54%
Biomea Fusion
Aug 6, 2026
Reiterated: Buy
Price Target: $9 → $7
Current: $1.27
Upside: +451.18%
Mirum Pharmaceuticals
Aug 6, 2026
Reiterated: Buy
Price Target: $146 → $137
Current: $82.93
Upside: +65.20%
Rhythm Pharmaceuticals
Aug 5, 2026
Reiterated: Buy
Price Target: $152 → $160
Current: $92.83
Upside: +72.36%
Annexon
Jul 21, 2026
Initiated Coverage: Sell
Price Target: $3
Current: $4.19
Upside: -28.40%
Jul 17, 2026
Reiterated: Buy
Price Target: $745 → $739
Current: $499.40
Upside: +47.98%
Jun 30, 2026
Reiterated: Buy
Price Target: $55
Current: $10.55
Upside: +421.33%
May 14, 2026
Reiterated: Buy
Price Target: $14 → $11
Current: $2.74
Upside: +302.19%
May 14, 2026
Reiterated: Buy
Price Target: $170 → $150
Current: $45.71
Upside: +228.16%
May 13, 2026
Reiterated: Buy
Price Target: $12 → $11
Current: $4.58
Upside: +140.17%
May 13, 2026
Reiterated: Buy
Price Target: $26 → $25
Current: $2.70
Upside: +825.93%
May 12, 2026
Reiterated: Buy
Price Target: $61 → $86
Current: $58.51
Upside: +46.98%
May 7, 2026
Reiterated: Buy
Price Target: $25 → $28
Current: $8.17
Upside: +242.72%
Mar 12, 2026
Reiterated: Buy
Price Target: $8
Current: $1.64
Upside: +389.30%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.96
Upside: -
Oct 23, 2025
Reiterated: Buy
Price Target: $8 → $11
Current: $4.81
Upside: +128.69%
Oct 6, 2025
Reiterated: Buy
Price Target: $18
Current: $2.96
Upside: +508.11%
Oct 6, 2025
Reiterated: Buy
Price Target: $120 → $32
Current: $1.68
Upside: +1,804.76%
May 23, 2025
Reiterated: Buy
Price Target: $19
Current: $6.09
Upside: n/a
Apr 23, 2025
Reiterated: Hold
Price Target: n/a
Current: $17.11
Upside: n/a
May 12, 2023
Reiterated: Buy
Price Target: $24
Current: $26.82
Upside: n/a